CAS
CPRX

Coppell Advisory Solutions’s Catalyst Pharmaceutical CPRX Stock Holding History

Coppell Advisory Solutions’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8
Closed -$169 – 627
2024
Q4 		$169 Hold
8
– – ﹤0.01% 1848
2024
Q3 		$156 Hold
8
– – ﹤0.01% 1752
2024
Q2 		$124 Buy
+8
New +$125 ﹤0.01% 1694

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Coppell Advisory Solutions's CPRX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 8 shares — an estimated $169 sold.

Coppell Advisory Solutions first reported a position in CPRX in Q2 2024 and held it in 3 quarters. The position peaked at $169 in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 8 Catalyst Pharmaceutical shares in Q1 2025, an estimated $169.
  • Coppell Advisory Solutions first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 3 quarters.
  • Coppell Advisory Solutions's Catalyst Pharmaceutical position peaked at $169 in Q4 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.